Goldman Sachs analyst James Quigley maintained a Buy rating on Bayer today and set a price target of €34.50. The company’s shares closed yesterday at €27.48.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Quigley covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Novartis AG, and Bayer. According to TipRanks, Quigley has an average return of -8.3% and a 38.85% success rate on recommended stocks.
Currently, the analyst consensus on Bayer is a Moderate Buy with an average price target of €27.72.
Based on Bayer’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of €10.74 billion and a GAAP net loss of €199 million. In comparison, last year the company earned a revenue of €11.14 billion and had a GAAP net loss of €34 million
Read More on GB:0P6S:
Disclaimer & DisclosureReport an Issue
- Bayer partners with Cornfed Farms to create ForwardFarm
- Bayer selects Interpublic as Creative agency partner
- Bayer Canada, Mint Pharmaceuticals enter distribution partnership for ADALAT XL
- Bristol Myers commitment a reminder of Veeva’s progress, says Stifel
- Bayer announces progress for two potential therapies for Parkinson’s disease
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
